Fig. 2

ROC curve analysis assessing the feasibility of serum irisin as a diagnostic indicator of breast cancer. Serum irisin can discriminate between breast cancer patients and healthy individuals at a cut-off point of 3.21 μg/ml, with 62.7 % sensitivity and 91.1 % specificity